InvestSMART

MGC Pharmaceuticals Ltd (ASX: MXC) - Announcements

Current share price for MXC : $0.420 0.01 (2.44%)+

ASX company news and announcements for MGC Pharmaceuticals Ltd (MXC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All MGC Pharmaceuticals Ltd (MXC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than MGC Pharmaceuticals Ltd (MXC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for MGC Pharmaceuticals Ltd (MXC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$18 Placement of $10m Closed Significantly Oversubscribed 17 Mar 2017 9:57AM $0.087 $0.420 risen by 382.76%
$18 Trading Halt 15 Mar 2017 9:29AM $0.087 $0.420 risen by 382.76%
$18 Conversion of Employee Performance Rights - Appendix 3B 7 Mar 2017 6:52PM $0.054 $0.420 risen by 677.78%
$18 Half Yearly Report and Accounts 28 Feb 2017 2:32PM $0.048 $0.420 risen by 775%
$18 Australian Legislation Changes Fast Track MXC 23 Feb 2017 10:01AM $0.044 $0.420 risen by 854.55%
$18 Cannabinoid Extraction Facility On Target Q2 Production 20 Feb 2017 9:53AM $0.038 $0.420 risen by 1,005.26%
$18 Release of Shares from Escrow - Appendix 3B 17 Feb 2017 6:48PM $0.038 $0.420 risen by 1,005.26%
$18 Medical Cannabis Clinical Study Commencing 14 Feb 2017 9:48AM $0.039 $0.420 risen by 976.92%
$18 Trading Halt 9 Feb 2017 8:05PM $0.039 $0.420 risen by 976.92%
$18 Panax Acquisition Completed 7 Feb 2017 9:47AM $0.040 $0.420 risen by 950%
$18 December Quarterly Activity and Cashflow Report 1 Feb 2017 8:25AM $0.037 $0.420 risen by 1,035.14%
$18 Commencement of Dermatological Clinical Trials 25 Jan 2017 10:58AM $0.041 $0.420 risen by 924.39%
$18 European CPNP Approval Granted for Derma Products 9 Jan 2017 9:53AM $0.042 $0.420 risen by 900%
$18 Appendix 3Y - Change of Director's Interest Notice 28 Dec 2016 8:06AM $0.041 $0.420 risen by 924.39%
$18 Issue of Performance Rights - Appendix 3B 23 Dec 2016 4:37PM $0.041 $0.420 risen by 924.39%
$18 MXC Operations Update 22 Dec 2016 11:52AM $0.041 $0.420 risen by 924.39%
$18 New Panax Acquisition Agreement Signed, Settlement Imminent 15 Dec 2016 9:55AM $0.043 $0.420 risen by 876.74%
$18 MXC Appoints ex Revlon Director to Fast Track Cosmetic Sales 7 Dec 2016 1:23PM $0.044 $0.420 risen by 854.55%
$18 First Major European Sales and Revenue for MGC Derma Range 2 Dec 2016 11:28AM $0.047 $0.420 risen by 793.62%
$18 Results of Annual General Meeting 29 Nov 2016 8:17PM $0.046 $0.420 risen by 813.04%
$18 Cleansing Prospectus Closed 10 Nov 2016 6:53PM $0.046 $0.420 risen by 813.04%
$18 Appendix 3B - Issue of Listed Options 10 Nov 2016 2:12PM $0.046 $0.420 risen by 813.04%
$18 Cleansing Prospectus 9 Nov 2016 4:22PM $0.042 $0.420 risen by 900%
$18 EU Registration Commenced for CBD Derma Product Sales 7 Nov 2016 10:06AM $0.046 $0.420 risen by 813.04%
$18 September Quarter Activity and Cashflow Report 27 Oct 2016 9:45AM $0.043 $0.420 risen by 876.74%

701 - 725 of 818 results

Page 29 of 33

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.